We report the results of a trial of recombinant leukocyte A interferon in previously treated patients with non-Hodgkin's lymphoma who were no longer responsive to chemotherapy. Patients received recombinant leukocyte A interferon (50 X 10(6) U per square meter of body-surface area) by intramuscular injection three times weekly for three months or longer. Forty-five patients were enrolled in the study, and 37 were evaluated for a response. Thirteen of 24 (54 per cent) evaluable patients with low-histologic-grade non-Hodgkin's lymphoma had objective responses (nine partial responses and four histologically confirmed complete responses). Two of six (33 per cent) with intermediate-grade lymphoma responded (one partially and one completely), and one of seven (14 per cent) with high-grade lymphoma had a partial response. The median duration of responses was eight months. Four of the five complete responders have continued to receive maintenance interferon and have been in complete remission for 3, 7, 9, and 12 months, respectively; one had a recurrence at a site of previous disease seven months after interferon had been stopped. Side effects were noted in most patients. All 16 responders had been heavily pretreated with combination chemotherapy, including doxorubicin in 8 of the 16. These results suggest that recombinant leukocyte A interferon may be an effective new therapy for some patients with low- and intermediate-grade non-Hodgkin's lymphoma.
This article has been cited by other articles:
Rohatiner, A.Z.S., Gregory, W.M., Peterson, B., Borden, E., Solal-Celigny, P., Hagenbeek, A., Fisher, R.I., Unterhalt, M., Arranz, R., Chisesi, T., Aviles, A., Lister, T.A.
(2005). Meta-Analysis to Evaluate the Role of Interferon in Follicular Lymphoma. JCO
23: 2215-2223
[Abstract][Full Text]
Cheson, B. D.
(2000). The Curious Case of the Baffling Biological. JCO
18: 2007-2009
[Full Text]
Solal-Celigny, P., Lepage, E., Brousse, N., Reyes, F., Haioun, C., Leporrier, M., Peuchmaur, M., Bosly, A., Parlier, Y., Brice, P., Coiffier, B., Gisselbrecht, C., The Groupe d'Etude des Lymphomes de l'Adulte,
(1993). Recombinant Interferon Alfa-2b Combined with a Regimen Containing Doxorubicin in Patients with Advanced Follicular Lymphoma. NEJM
329: 1608-1614
[Abstract][Full Text]
Foon, K. A., Rai, K. R., Gale, R. P.
(1990). Chronic Lymphocytic Leukemia: New Insights into Biology and Therapy. ANN INTERN MED
113: 525-539
[Abstract]
Isner, J. M., Dietz, W. A.
(1988). Cardiovascular Consequences of Recombinant DNA Technology: Interleukin-2. ANN INTERN MED
109: 933-935
[Abstract]
Hanker, J., Giammara, B.
(1988). Biomaterials and biomedical devices. Science
242: 885-892
[Abstract]
Vonderheid, E. C., Thompson, R., Smiles, K. A., Lattanand, A.
(1987). Recombinant Interferon Alfa-2b in Plaque-Phase Mycosis Fungoides: Intralesional and Low-Dose Intramuscular Therapy. Arch Dermatol
123: 757-763
[Abstract]
CHESON, B. D., MARTIN, A.
(1987). Clinical Trials in Hairy Cell Leukemia: Current Status and Future Directions. ANN INTERN MED
106: 871-878
[Abstract]
FAUCI, A. S., ROSENBERG, S. A., SHERWIN, S. A., DINARELLO, C. A., LONGO, D. L., LANE, H. C.
(1987). Immunomodulators in Clinical Medicine. ANN INTERN MED
106: 421-433
[Abstract]
FAHEY, J. L., SARNA, G., GALE, R. P., SEEGER, R.
(1987). Immune Interventions in Disease. ANN INTERN MED
106: 257-274
[Abstract]
AKARD, L. P., HOFFMAN, R., ELIAS, L., SAIERS, J. H.
(1986). Alpha-Interferon and Immune Hemolytic Anemia. ANN INTERN MED
105: 306-306
[Abstract]
CHAMPLIN, R., GALE, R. P., FOON, K. A., GOLDE, D. W.
(1986). Chronic Leukemias: Oncogenes, Chromosomes, and Advances in Therapy. ANN INTERN MED
104: 671-688
[Abstract]
GALE, R. P., FOON, K. A.
(1985). Chronic Lymphocytic Leukemia: Recent Advances in Biology and Treatment. ANN INTERN MED
103: 101-120
[Abstract]
Previous
